<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528580</url>
  </required_header>
  <id_info>
    <org_study_id>15420A</org_study_id>
    <nct_id>NCT00528580</nct_id>
  </id_info>
  <brief_title>Statins for the Early Treatment of Sepsis</brief_title>
  <acronym>SETS</acronym>
  <official_title>Statins for the Early Treatment of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a Phase II, randomized, placebo-controlled clinical trial to test the hypothesis
      that treatment with once-daily statins has a beneficial effect on inflammatory cytokines and
      clinical outcomes in adults hospitalized with sepsis. As our animal models suggest
      pretreatment with statins are required for their beneficial effects, we propose a study
      design intended to identify patients and initiate treatment early in their hospital stay.
      This Phase II study is intended to assess the feasibility of conducting a large-scale
      investigator-initiated translational research protocol that involves multiple clinical
      services within the Department of Medicine.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate recruitment
  </why_stopped>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Clinical Stability</measure>
    <time_frame>24 hours</time_frame>
    <description>Normalization of vital signs for each subject enrolled. This is expressed as a mean time to normalization for each +/- standard error.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 80 mg once daily PO (or via NG or G-tube)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical-appearing placebo PO (or via NG or G-tube)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>80 mg once daily PO/NG x 4 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Identical-appearing placebo</intervention_name>
    <description>once daily x 4 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Initial presentation to the Emergency Department or University of Chicago MD
             office/Dialysis Center for current hospital admission

          -  Sepsis (ACCP/SCCM criteria)

               1. Clinically suspected infection as per the treating physician or confirmed
                  infection

               2. 2 or more of the following: Temperature 38ºC (100.4ºF)or 36ºC (96.8ºF), Heart
                  rate (HR) &gt; 90/min, Respiratory rate (RR) &gt; 20/min or PaCO2 &lt; 32 mmHg, White
                  blood cell count &gt; 12,000/mm3 or &lt; 4000/m3 or &gt; 10%immature neutrophils

          -  Initiation of antibiotics by treating physician for sepsis

          -  Hospitalized from the Emergency Department or University of Chicago MD office/Dialysis
             Center to an inpatient medical service (intensive care unit (ICU)or non-ICU service)
             OR admission to the medical ICU (MICU) from a non-ICU inpatient medical floor.

          -  Assent of the primary treating physician at the time of enrollment.

          -  The meeting of SIRS criteria is due to an infection as per the treating physician.

        Exclusion Criteria:

          -  Pregnancy

          -  ALT &gt;3 times above the upper limit of normal

          -  Elevated creatine phosphokinase (CPK) (&gt;3 times the upper limit of normal)

          -  Concurrent treatment with any of the following drugs: daptomycin, fenofibrate,
             ketoconazole,triaconazole, amiodarone, clarithromycin, cyclosporine,
             erythromycin,nefazodone, niacin, protease inhibitors, telithromycin,
             verapamil,danazol, gemfibrozil

          -  History of allergy or intolerance to statins

          -  Greater than 16 hours after meeting inclusion criteria

          -  Use of 1 more doses of statins in the previous 4 weeks

          -  Clinical indication for treatment with statin during hospital admission (per treating
             physician)

          -  Sufficiently poor prognosis prior to enrollment that treating physicians have elected
             to employ comfort care or plan to discharge to hospice

          -  Transfer from surgical service to medical service

          -  Needing transfusion for either active bleeding or severe hemolysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Krishnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Oba Y, Salzman GA. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury. N Engl J Med. 2000 Sep 14;343(11):813; author reply 813-4.</citation>
    <PMID>10991706</PMID>
  </reference>
  <reference>
    <citation>Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004 Aug 17;110(7):880-5. Epub 2004 Aug 2.</citation>
    <PMID>15289367</PMID>
  </reference>
  <reference>
    <citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992 Jun;20(6):864-74. Review.</citation>
    <PMID>1597042</PMID>
  </reference>
  <reference>
    <citation>Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003 Sep 15;37(6):752-60. Epub 2003 Aug 28. Erratum in: Clin Infect Dis. 2003 Oct 15;37(8):1147.</citation>
    <PMID>12955634</PMID>
  </reference>
  <reference>
    <citation>Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003 May;17(8):905-7. doi: 10.1096/fj.02-1014fje. Epub 2003 Mar 5.</citation>
    <PMID>12626426</PMID>
  </reference>
  <reference>
    <citation>Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, Fox CS, Levin NW, Powe NR. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA. 2007 Apr 4;297(13):1455-64. Erratum in: JAMA. 2008 Feb 20;299(7):765.</citation>
    <PMID>17405971</PMID>
  </reference>
  <reference>
    <citation>Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006 Feb 4;367(9508):413-8.</citation>
    <PMID>16458766</PMID>
  </reference>
  <reference>
    <citation>Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005 Jun;288(6):L1026-32. Epub 2005 Jan 21.</citation>
    <PMID>15665042</PMID>
  </reference>
  <reference>
    <citation>Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003 Feb 1;170(3):1524-30.</citation>
    <PMID>12538717</PMID>
  </reference>
  <reference>
    <citation>Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001 Oct 15;33(8):1352-7. Epub 2001 Sep 20.</citation>
    <PMID>11565076</PMID>
  </reference>
  <reference>
    <citation>Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006 Nov 11;333(7576):999. Epub 2006 Oct 23.</citation>
    <PMID>17060337</PMID>
  </reference>
  <reference>
    <citation>Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C. Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005 Jul 5;112(1):117-24.</citation>
    <PMID>15998696</PMID>
  </reference>
  <reference>
    <citation>Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C, Mulligan MS. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg. 2003 Aug;126(2):482-9.</citation>
    <PMID>12928648</PMID>
  </reference>
  <reference>
    <citation>Schmidt H, Hennen R, Keller A, Russ M, Müller-Werdan U, Werdan K, Buerke M. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med. 2006 Aug;32(8):1248-51. Epub 2006 Jun 21.</citation>
    <PMID>16788803</PMID>
  </reference>
  <reference>
    <citation>Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC, Lervang HH. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006 Apr;34(4):1080-6.</citation>
    <PMID>16484926</PMID>
  </reference>
  <reference>
    <citation>Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006 May;69(9):1535-42.</citation>
    <PMID>16557230</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>May 7, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2018</results_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Statin</keyword>
  <keyword>Infection</keyword>
  <keyword>Immunomodulatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled 2008-2009 at University of Chicago and Mercy Hosptial in Chicago, IL</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Simvastatin 80 mg once daily PO (or via NG or G-tube)
Simvastatin: 80 mg once daily PO/NG x 4 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Identical-appearing placebo PO (or via NG or G-tube)
Identical-appearing placebo: once daily x 4 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Simvastatin 80 mg once daily PO (or via NG or G-tube)
Simvastatin: 80 mg once daily PO/NG x 4 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identical-appearing placebo PO (or via NG or G-tube)
Identical-appearing placebo: once daily x 4 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="8"/>
                    <measurement group_id="B2" value="52" spread="8"/>
                    <measurement group_id="B3" value="52" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Clinical Stability</title>
        <description>Normalization of vital signs for each subject enrolled. This is expressed as a mean time to normalization for each +/- standard error.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Simvastatin 80 mg once daily PO (or via NG or G-tube)
Simvastatin: 80 mg once daily PO/NG x 4 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Identical-appearing placebo PO (or via NG or G-tube)
Identical-appearing placebo: once daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Stability</title>
          <description>Normalization of vital signs for each subject enrolled. This is expressed as a mean time to normalization for each +/- standard error.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1"/>
                    <measurement group_id="O2" value="3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>Simvastatin 80 mg once daily PO (or via NG or G-tube)
Simvastatin: 80 mg once daily PO/NG x 4 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identical-appearing placebo PO (or via NG or G-tube)
Identical-appearing placebo: once daily x 4 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Millie Maleckar</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-1472</phone>
      <email>mmalecka@bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

